Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists

Circulation

Volumn 101, Issue 9, 2000, Pages 1013-1018

  Michelson, Alan D ^b   Furman, Mark I ^b   Goldschmidt Clermont, Pascal ^c   Mascelli, Mary Ann ^d   Hendrix, Craig ^a   Coleman, Lindsay ^a   Hamlington, Jeanette ^a   Barnard, Marc R ^b   Kickler, Thomas ^a   Christie, Douglas J ^e   Kundu, Sourav ^e   Bray, Paul F ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d CENTOCOR INC   (United States)

^e Dade Behring Inc   (United States)

Author keywords

Coronary disease; Inhibitors; Platelets; Polymorphisms

Indexed keywords

ABCIXIMAB; FIBRINOGEN RECEPTOR;

ARTICLE; ATHEROSCLEROTIC PLAQUE; CORONARY ARTERY DISEASE; FLOW CYTOMETRY; GENE DOSAGE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HUMAN CELL; MEMBRANE BINDING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

EID: 18244414272     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.101.9.1013     Document Type: Article

References (23)

1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 1992;326:242-250, 310-318.
2. Trip MD, Cats VM, van Capelle FJ, Vreeken J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med. 1990;322:1549-1554.
3. A2: an inherited platelet risk factor for coronary thrombotic events. N Engl J Med. 1996;334:1090-1094.
4. Pastinen T, Perola M, Niini P, Terwilliger J, Salomaa V, Vartiainen E, Peltonen L, Syvänen A-C. Array-based multiplex analysis of candidate genes reveals two independent and additive genetic risk factors for myocardial infarction in the Finnish population. Hum Mol Genet. 1998;7: 1453-1462.
5. von dem Borne A, Decary F. Nomenclature of platelet specific antigens. Transfusion. 1990;30:477.
6. Gear AR, Lambrecht JK. Reduction in single platelets during primary and secondary aggregation. Thromb Haemost. 1981;45:298.
7. Michelson A. Flow cytometry: a clinical test of platelet function. Blood. 1996;87:4925-4936.
8. Gralnick H, Williams S, McKeown L, Connaghan G, Shafer B, Hansmann K, Vail M, Fenton J. Endogenous platelet fibrinogen surface expression on activated platelets. J Lab Clin Med. 1991;118:604-613.
9. Frelinger A, Cohen I, Plow E, Smith M, Roberts J, Lam S, Ginsberg M. Selective inhibition of integrin function by antibodies specific for ligand-occupied receptor conformers. J Biol Chem. 1990;265:6346-6352.
10. Stenberg P, McEver R, Shuman M, Jacques Y, Bainton D. A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J Cell Biol. 1985;101:880-886.
11. Farady N, Goldschmidt-Clermont P, Dise K, Bray P. Quantitation of soluble fibrinogen binding to platelets by fluorescence activated flow cytometry. J Lab Clin Med. 1994;123:728-740.
12. Wagner C, Mascelli M, Neblock D, Weisman H, Coller B, Jordon R. Analysis of GP IIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood. 1996;88:907-914.
13. Holford N, Sheiner L. Kinetics of pharmacologic response. Pharmacol Ther. 1982;16:143-166.
14. Marguerie G, Edgington T, Plow E. Interaction of fibrinogen with its platelet receptor as part of a multistep reaction in ADP-induced platelet aggregation. J Biol Chem. 1980;255:154-161.
15. Lutomski D, Bottorff M, Sangha K. Pharmacokinetic optimization of the treatment of embolic disorders. J Clin Pharmacol. 1995;28:67-92.
16. A2 polymorphism and efficacy of aspirin. Lancet. 1998;351:1353-1354.
17. Coller B. Platelet GP IIb/IIIa antagonists: the first anti-integrin receptor therapeutics. J Clin Invest. 1997;100:S57-S60.
18. Jordan RE, Wagner CL, Mascelli MA, Treacy G, Nedelman MA, Woody JN, Weisman HF, Coller BS. Preclinical development of c7E3 Fab: a mouse/human chimeric monoclonal antibody fragment that inhibits platelet function by blockade of GP IIb/IIIa receptors with observations on the immunogenicity of c7E3 Fab in humans. In: Horton MA, ed. Adhesion Receptors as Therapeutic Targets. Boca Raton, Fla: CRC Press Inc; 281-305:1996.
19. A2 polymorphism: the Framingham Offspring Study. Arterioscler Thromb Vasc Biol. 1999;19:1142-1147.
20. Frojmovic MM, Mooney RF, Wong T. Dynamics of platelet glycoprotein IIb-IIIa receptor expression and fibrinogen binding, I: quantal activation of platelet subpopulations varies with adenosine diphosphate concentration. Biophys J. 1994;67:2060-2068.
21. Goto S, Ikeda Y, Saldivar E, Ruggeri ZM. Distinct mechanisms of platelet aggregation as a consequence of different shearing flow conditions. J Clin Invest. 1998;101:479-486.
22. Shattil S, Kashiwagi H, Pampori N. Integrin signaling: the platelet paradigm. Blood. 1998;91:2645-2657.
23. 3. Blood. 1998;92:343a. Abstract.